Supraventricular tachycardia In individuals with supraventricular tachycardia (SVT),<unk>  is used to help identify and convert the rhythm. Certain SVTs can be successfully terminated with<unk> . This includes any re-entrant arrhythmias that require the AV node for the re-entry, e.g., AV reentrant tachycardia (AVRT), AV nodal reentrant tachycardia (AVNRT). In<unk> dition, atrial tachycardia can sometimes be terminated with<unk> . Fast rhythms of the heart that are confined to the atria (e.g., atrial fibrillation, atrial flutter) or ventricles (e.g., monomorphic ventricular tachycardia) and do not involve the AV node as part of the re-entrant circuit are not typically converted by<unk> . However, the ventricular response rate is temporarily slowed with<unk>  in such cases. Because of the effects of<unk>  on AV node-dependent SVTs,<unk>  is considered a class V antiarrhythmic agent. When<unk>  is used to cardiovert an abnormal rhythm, it is normal for the heart to enter ventricular asystole for a few seconds. This can be disconcerting to a normally conscious patient, and is associated with angina-like sensations in the chest. Nuclear stress test<unk>  is used as an<unk> junct to thallium (TI 201) or technetium (Tc99m) myocardial perfusion scintigraphy (nuclear stress test) in patients unable to undergo<unk> quate stress testing with exercise. Dosage When given for the evaluation or treatment of a supraventricular tachycardia (SVT), the initial dose is 6 mg to 12 mg, depending on standing orders or provider preference, given as a rapid parenteral infusion. Due to<unk> 's extremely short half-life, the IV line is started as proximal (near) to the heart as possible, such as the antecubital fossa. The IV push is often followed with a flush of 10–20 mL of normal saline. If this has no effect (i.e., no evidence of transient AV block), a dose of 12 mg can be given 1–2 minutes after the first dose. When given to dilate the arteries, such as in a "stress test", the dosage is typically 0.14 mg/kg/min,<unk> ministered for 4 or 6 minutes, depending on the protocol. The recommended dose may be increased in patients on theophylline since methylxanthines prevent binding of<unk>  at receptor sites. The dose is often decreased in patients on dipyridamole (Persantine) and diazepam (Valium) because<unk>  potentiates the effects of these drugs. The recommended dose is also reduced by half in patients presenting congestive heart failure, myocardial infarction, shock, hypoxia, and/or chronic liver disease or chronic kidney disease, and in elderly patients.
Adenosine
Dobutamine
Adrenaline
Nortilidine
Norepinephrine 
Norepinephrine
Iofetamine 
Epinephrine 